Literature DB >> 15384983

Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization.

Giuseppe D Norata1, Cristina Banfi, Angela Pirillo, Elena Tremoli, Anders Hamsten, Alberico L Catapano, Per Eriksson.   

Abstract

Modified lipoproteins have been suggested to modulate endothelial expression of plasminogen activator inhibitor-1 (PAI-1). As oxidized high-density lipoprotein (Ox-HDL) has been found in atheromatous plaques and receptors for modified HDL are present on endothelial cells, we investigated the role of Ox-HDL3 on the expression of PAI-1. Ox-HDL3 but not native HDL3, increased PAI-1 mRNA expression in endothelial cells. Furthermore, PAI-1 antigen expression and activity increased in the supernatant of cells incubated with Ox-HDL3. The intracellular pathways involved in this effect were investigated. Ox-HDL3 activated both extracellular signal-regulated kinases (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK). Moreover, incubation with specific inhibitors of these kinases showed that p38MAPK was mainly involved in the Ox-HDL3-dependent PAI-1 induction. Transient transfection experiments suggested that none of the response elements in the proximal promoter (-804 to 17) were involved in Ox-HDL3-mediated PAI-1 expression. mRNA stability experiments showed that Ox-HDL3 increased the PAI-1 mRNA half-life. In summary, Ox-HDL3 induced PAI-1 mRNA expression and antigen release through a molecular mechanism involving MAPK activation and mRNA stabilization. Thus, oxidative modification converts HDL to a prothrombotic lipoprotein species. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384983     DOI: 10.1111/j.1365-2141.2004.05163.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  oxHDL decreases the expression of CD36 on human macrophages through PPARgamma and p38 MAP kinase dependent mechanisms.

Authors:  Jingyi Ren; Wenying Jin; Hong Chen
Journal:  Mol Cell Biochem       Date:  2010-05-11       Impact factor: 3.396

2.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells.

Authors:  Yasushi Mukai; Chao-Yung Wang; Yoshiyuki Rikitake; James K Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-15       Impact factor: 4.733

4.  Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2009-08

Review 5.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

6.  Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

Authors:  Massimiliano Ruscica; Chiara Ricci; Chiara Macchi; Paolo Magni; Riccardo Cristofani; Jingwen Liu; Alberto Corsini; Nicola Ferri
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

Review 7.  HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases.

Authors:  Fabrizia Bonacina; Angela Pirillo; Alberico L Catapano; Giuseppe D Norata
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 8.  Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium.

Authors:  Giuseppe D Norata; Alberico L Catapano
Journal:  Vasc Health Risk Manag       Date:  2005

9.  Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis.

Authors:  F Bonacina; L Da Dalt; A L Catapano; G D Norata
Journal:  Mol Aspects Med       Date:  2020-10-05

Review 10.  The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Magdalena Rysz-Górzyńska; Beata Franczyk
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.